[Transfer] Vice President Johnson & Johnson leaves, only 8 months promoted

Source: Siqi Club/Su Mang, Janessa

Recently, according to the industry media Endpoints News, Pharmaceutical (R & D) Mathai Mammen chose to leave Johnson & Johnson, and will seek external professional opportunities in the company. At present, Mammen is no longer among the "Executive Committee" page of Johnson & Johnson's official website.

According to reports, before determining the new leadership, William HAIT temporarily served as the temporary person in charge of Johnson & Johnson Pharmaceutical.

In 2017, Mammen jumped from Merhadon to Johnson & Johnson and replaced HAIT as the director of pharmaceutical research and development. Until January this year, Mammen was officially appointed as a senior leader of Johnson & Johnson Executive Committee. However, after only 8 months, Mammen chose to leave.

After graduating from Harvard University, Mammen and two other industry workers jointly founded Theravance in 1997. During the 17 years, Mammen initiated and led a number of projects, of which 4 drugs were approved by the FDA. In 2014, theravance launched the R & D team of R & D by Mammen and leading about 200 R & D teams. These R & D experience paved the way for Mammen to serve as the head of R & D in large pharmaceutical companies.

Subsequently, after he transferred to Innoviva as the vice president of R & D, he returned to Theravance again. In 2016, MAMMEN entered Merckon and served as senior vice president. He was mainly responsible for cardiovascular disease, metabolic diseases, immunology, and oncology. He was once trained by the company as the successor of Merck's research and development leader Roger Perlmutter.

"Bold" bet

During Johnson & Johnson's tenure, Mammen has maintained an innovation -oriented perspective and discovered innovation potential, so he also made a lot of "bold" bets. For example, Johnson & Johnson Yang Sen cooperates with the BCMA Car-T project of the legendary creature.

In June 2017, the legendary BCMA CAR-T was unveiled at the Annual Meeting of the American Clinical Oncology Society (ASCO), which announced the research results of the late recurrence or refractory (R/R) multiple osteomyoma tumors named LCAR-B38M at the time. Data show that of 35 patients who received legendary creature CART treatment, 33 people (94%) were clinically relieved 2 months after treatment, and the objective relief rate was 100%.

This outstanding data has aroused widespread attention in the industry, and also contributed to the cooperation between Johnson & Johnson Yang Sen and legendary creatures. According to the cooperation agreement, Johnson & Johnson pays a $ 350 million down payment and subsequent milestone payment to the legendary biology. Although today, the $ 350 million down payment was not high, but at the time, it was also the highest record and the best condition for the maximum amount of down payment for Chinese pharmaceutical companies' foreign patents.

In February this year, the FDA officially approved the listing of Legendary BCMA Car-T CARVYKTI for the treatment of patients with recurrence/refractory multiple bone marrow tumors (R/R MM). As of June 30, 2022, Carvykti has generated a total of about $ 24 million in net trade sales.

This cooperation not only made the first domestic CAR-T successfully listed in the US market, but also allowed Johnson & Johnson to win in the CAR-T field.

It is worth noting that at this year's ASCO conference, legendary creatures also showed the results of CARTITUTUDE-2 (NCT04133636), which was also demonstrated. The effectiveness proves the prospect of carvykti for early treatment of multiple osteoma.

Perhaps it can be said that Carvykti's sales in the first half of this year are just the beginning, and it is expected to open a wider market space in the future.

Johnson

At the end of last year, Johnson & Johnson announced the merger of the spin -off plan -pharmaceutical and medical device business, and consumer health care business was independent, and two listed companies were established. Johnson & Johnson expects that the architecture of the new consumer health company is expected to be completed by the end of 2022.

Entering 2022, Johnson & Johnson's performance continued to rise. According to the latest semi -annual report, Johnson & Johnson's sales reached 47.446 billion US dollars, a year -on -year increase of 4%. Among them, the pharmaceutical business revenue was US $ 26.186 billion in the first half of the year; the medical device business revenue was US $ 13.869 billion in the first half of the year; the consumer health business revenue reached US $ 7.391 billion in the first half of the year.

Such performance will successfully send Johnson & Johnson to the second place in the performance ranking of multinational pharmaceutical companies in the first half of the year, and there is still a gap of $ 6 billion from Pfizer.

Among all businesses, Johnson & Johnson Pharmaceutical's contribution has the largest sales. The driving factor of growth in performance is mainly due to the fields of autoimmune diseases, tumors, anti -infection, pulmonary hypertension and other fields. The growth is mainly Stelara, Darzalex (Darefu Small Mipide), IMBRUVICA (Ebininib), TREMFYA (Geisicy), EricAda Promotion of model products. However, it can be seen from the semi -annual report that although the "heavy product" still brings a certain income to Johnson & Johnson, there are also many single products that have stagnated sales, and even the contradiction between revenue growth and net profit decline.

As the market continues to recover, Johnson & Johnson is expected to have a stronger business performance in the second half of the year, but the expected sales expectations of the whole year will be reduced. The income target will be reduced from the original plan of US $ 94.95.8 billion to 93.3 billion to 94.3 billion US dollars, a decrease of 1.7% Essence

In the past year, Johnson & Johnson's important position has changed twice

In August 2021, Johnson & Johnson announced that Johnson & Johnson, who has been at the helm for 9 years, handed his position to Duato. Alex was the chairman of the board of directors.

Gorsky has been the chairman and CEO of Johnson & Johnson since 2012. During his tenure, Gorsky supervised research and development investment in 2020. This content increased by more than 60%to $ 12 billion. It also carried out hundreds of acquisitions and cooperation. One of the main points of R & D investment was oncology. Sales in this field increased from approximately $ 2 billion in 2011 to more than $ 12 billion in 2020.

Regarding the reason for the departure, Alex Gorsky pointed out, "I have witnessed the company's development and expansion in the 30 years of Johnson & Johnson. In the past ten years, Johnson & Johnson has changed, which has greatly increased R & D investment and promoted some of the most the most. Important global healthcare progress, the overall business has undergone major strategic transformations and achieved recorded results. Due to family health reasons, I focus on my family, which is also a suitable time for me. "

Following the CEO announced 2 months after resignation, Johnson & Johnson announced that Paul Stoffels, chief scientific officer, plans to retire and step down by the end of this year.

During Johnson, Stoffels established a strong R & D pipeline, and also supervised the R & D of Johnson & Johnson's new generation of vaccines. His departure marks that within a year, the largest pharmaceutical dealer in the United States announced the second time that the vacancies of important positions need to be supplemented.

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -